Exhibits LRR domain binding activity and phosphatase binding activity. Involved in several processes, including axon development; positive regulation of cardiac muscle cell proliferation; and thalamus development. Localizes to several cellular components, including Schaffer collateral - CA1 synapse; glutamatergic synapse; and integral component of synaptic membrane. Used to study middle cerebral artery infarction. Biomarker of Alzheimer's disease; congestive heart failure; hypothyroidism; mental depression; and myocardial infarction. Human ortholog(s) of this gene implicated in bipolar disorder; middle cerebral artery infarction; and pancreatic cancer. Orthologous to human NCAM1 (neural cell adhesion molecule 1); PARTICIPATES IN fibroblast growth factor signaling pathway; prion disease pathway; INTERACTS WITH 1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine; 17beta-estradiol; 2,2',4,4'-Tetrabromodiphenyl ether.
nickel chloride promotes the reaction [Tretinoin results in increased expression of NCAM1 mRNA], nickel chloride promotes the reaction [Tretinoin results in increased expression of NCAM1 protein]
[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of NCAM1 more ...
[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of NCAM1 more ...
Ashwagandha inhibits the reaction [lead nitrate results in decreased expression of NCAM1 mRNA], Ashwagandha inhibits the reaction [lead nitrate results in decreased expression of NCAM1 protein]
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of NCAM1 mRNA
nickel chloride promotes the reaction [Tretinoin results in increased expression of NCAM1 mRNA], nickel chloride promotes the reaction [Tretinoin results in increased expression of NCAM1 protein]
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of NCAM1 mRNA
perfluorooctane sulfonic acid results in increased expression of NCAM1 mRNA, perfluorooctane sulfonic acid results in increased expression of NCAM1 protein
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of NCAM1 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of NCAM1 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin